Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2014

Open Access 01-12-2014 | Original research

Toxicity and radiation dosimetry studies of the serotonin transporter radioligand [18 F]AFM in rats and monkeys

Authors: Ya-Yao Huang, Chen-Yi Cheng, Wen-Sheng Huang, Kuo-Hsing Ma, Ta-Wei Tseng, Ta-Kai Chou, Yiyun Huang, Chyng-Yann Shiue

Published in: EJNMMI Research | Issue 1/2014

Login to get access

Abstract

Background

[18 F]AFM is a potent and promising PET imaging agent for the serotonin transporter. We carried out an acute toxicity study in rats and radiation dosimetry in monkeys before the translation of the tracer to humans.

Methods

Single- and multiple-dose toxicity studies were conducted in Sprague–Dawley rats. Male and female rats were injected intravenously with AFM tartrate as a single dose of 98.7 or 987 μg/kg (592 or 5,920 μg/m2, 100× or 1,000× the proposed human dose of 8 μg, respectively) on day 1 or as five consecutive daily doses of 98.7 μg/kg/day (592 μg /m2/day, 100× human dose, total dose 493.5 μg/kg). PET/CT scans were performed in four Formosan rock monkeys (two males and two females, each monkey scanned twice) using a Siemens BIOGRAPH scanner. After injection of [18 F]AFM (88.5 ± 20.3 MBq), a low-dose CT scan and a series of eight whole-body PET scans in 3-D mode were performed. Time-activity data of source organs were used to calculate the residence times and estimate the absorbed radiation dose using the OLINDA/EXM software.

Results

In the rats, neither the single dose nor the five daily doses of AFM tartrate produced overt adverse effects clinically. In the monkeys, the radiation doses received by most organs ranged between 8.3 and 39.1 μGy/MBq. The osteogenic cells, red marrow, and lungs received the highest doses of 39.1, 35.4, and 35.1 μGy/MBq, respectively. The effective doses extrapolated to male and female adult humans were 18.0 and 18.3 μSv/MBq, respectively.

Conclusions

Toxicity studies in Sprague–Dawley rats and radiation dosimetry studies in Formosa rock monkeys suggest that [18 F]AFM is safe for use in human PET imaging studies.

Trial registration

IACUC-12-200.
Literature
1.
Mann JJ: Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999, 21:99S–105S.CrossRefPubMed
2.
Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF 3rd: Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology 1998, 18:407–430.CrossRefPubMed
3.
4.
Horschitz S, Hummerich R, Schloss P: Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor. Neuroreport 2001, 12:2181–2184.CrossRefPubMed
5.
Brust P, Hesse S, Mueller U, Szabo Z: Neuroimaging of the serotonin transporter: possibilities and pitfalls. Curr Psychiatry Rev 2006, 2:111–149.CrossRef
6.
Szabo Z, Kao PF, Scheffel U, Suehiro M, Mathews WB, Ravert HT, Musachio JL, Marenco S, Kim SE, Ricaurte GA, Wong DF, Wagner HN Jr, Dannals RF: Positron emission tomography imaging of serotonin transporters in the human brain using [ 11 C](+)McN5652. Synapse 1995, 20:37–43.CrossRefPubMed
7.
Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, Slifstein M, Van Heertum RL, Mann JJ, Laruelle M: In vivo quantification of brain serotonin transporters in humans using [ 11 C]McN 5652. J Nucl Med 2000, 41:1465–1477.PubMed
8.
Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V: Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006, 163:52–58.CrossRefPubMed
9.
Frankle W, Huang Y, Hwang D, Talbot P, Slifstein M, Van Heertum R, Abi-Dargham A, Laruelle M: Comparative evaluation of serotonin transporter radioligands 11 C-DASB and 11 C-McN5652 in healthy humans. J Nucl Med 2004, 45:682–694.PubMed
10.
Suehiro M, Greenberg JH, Shiue CY, Gonzalez C, Dembowski B, Reivich M: Radiosynthesis and biodistribution of the S -[ 18   F]fluoroethyl analog of McN5652. Nucl Med Biol 1996, 23:407–412.CrossRefPubMed
11.
Zessin J, Eskola O, Brust P, Bergman J, Steinbach J, Lehikoinen P, Solin O, Johannsen B: Synthesis of S -([ 18 F]fluoromethyl)-(+)-McN5652 as a potential PET radioligand for the serotonin transporter. Nucl Med Biol 2001, 28:857–863.CrossRefPubMed
12.
Hesse S, Brust P, Mäding P, Becker GA, Patt M, Seese A, Sorger D, Zessin J, Meyer PM, Lobsien D: Imaging of the brain serotonin transporters (SERT) with 18   F-labelled fluoromethyl-McN5652 and PET in humans. Eur J Nucl Med Mol Imaging 2012, 39:1–11.
13.
Ferris RM, Brieaddy L, Mehta N, Hollingsworth E, Rigdon G, Wang C, Soroko F, Wastila W, Cooper B: Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine- and noradrenaline-reuptake inhibitor. J Pharm Pharmacol 1995, 47:775–781.CrossRefPubMed
14.
Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S: Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11 C-labeled 2-(phenylthio) araalkylamines. J Med Chem 2000, 43:3103–3110.CrossRefPubMed
15.
Huang Y, Hwang DR, Bae SA, Sudo Y, Guo N, Zhu Z, Narendran R, Laruelle M: A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [ 11 C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([ 11 C]AFM). Nucl Med Biol 2004, 31:543–556.CrossRefPubMed
16.
Tarkiainen J, Vercouillie J, Emond P, Sandell J, Hiltunen J, Frangin Y, Guilloteau D, Halldin C: Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter. J Labelled Cpd Radiopharm 2001, 44:1013–1023.CrossRef
17.
Jarkas N, Votaw JR, Voll RJ, Williams L, Camp VM, Owens MJ, Purselle DC, Bremner JD, Kilts CD, Nemeroff CB: Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters. Nucl Med Biol 2005, 32:211–224.CrossRefPubMed
18.
Nye JA, Votaw JR, Jarkas N, Purselle D, Camp V, Bremner JD, Kilts CD, Nemeroff CB, Goodman MM: Compartmental modeling of 11 C-HOMADAM binding to the serotonin transporter in the healthy human brain. J Nucl Med 2008, 49:2018–2025.CrossRefPubMedPubMedCentral
19.
Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S: Positron emission tomography quantification of [ 11 C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001, 21:1342–1353.CrossRefPubMed
20.
Nabulsi N, Williams W, Planeta-Wilson B, Labaree D, Ropchan J, Neumeister A, Carson R, Huang Y: The serotonin transporter tracer [C-11] AFM provides high specific binding signals in humans. J Nucl Med 2008, 49:80P.
21.
Lundberg J, Odano I, Olsson H, Halldin C, Farde L: Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med 2005, 46:1505–1515.PubMed
22.
Oya S, Choi SR, Coenen H, Kung HF: New PET imaging agent for the serotonin transporter: [18 F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N, N-dimethyl-benzenmethanamine). J Med Chem 2002, 45:4716–4723.CrossRefPubMed
23.
Huang YY, Huang WS, Chu TC, Shiue CY: An improved synthesis of 4-[ 18   F]-ADAM, a potent serotonin transporter imaging agent. Appl Radiat Isot 2009, 67:1063–1067.CrossRefPubMed
24.
Shiue GG, Fang P, Shiue CY: Synthesis of N, N-dimethyl-2-(2-amino-4-[18 F] fluorophenylthio) benzylamine as a serotonin transporter imaging agent. Appl Radiat Isot 2003, 58:183–191.CrossRefPubMed
25.
Peng CJ, Huang YY, Huang WS, Shiue CY: An automated synthesis of N, N-dimethyl-2-(2-amino-4-[18 F]fluorophenylthio) benzylamine (4-[18 F]-ADAM) for imaging serotonin transporters. Appl Radiat Isot 2008, 66:625–631.CrossRefPubMed
26.
Fang P, Shiue GG, Shimazu T, Greenberg JH, Shiue CY: Synthesis and evaluation of N, N-dimethyl-2-(2-amino-5-[18 F]fluorophenylthio)benzylamine as a serotonin transporter imaging agent. Appl Radiat Isot 2004, 61:1247–1254.CrossRefPubMed
27.
Huang Y, Bae SA, Zhu Z, Guo N, Roth BL, Laruelle M: Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. J Med Chem 2005, 48:2559–2570.CrossRefPubMed
28.
Parhi AK, Wang JL, Oya S, Choi SR, Kung MP, Kung HF: 2-(2′-((Dimethylamino) methyl)-4′-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents. J Med Chem 2007, 50:6673–6684.CrossRefPubMedPubMedCentral
29.
Garg S, Thopate SR, Minton RC, Kimberly W, Lynch AJH, Garg PK: 3-Amino-4-(2-((4-[ 18   F]fluorobenzyl) methylamino) methylphenylsulfanyl) benzonitrile, an F-18 fluorobenzyl analogue of DASB: synthesis, in vitro binding, and in vivo biodistribution studies. Bioconjug Chem 2007, 18:1612–1618.CrossRefPubMed
30.
Shiue GG, Choi SR, Fang P, Hou C, Acton PD, Cardi C, Saffer JR, Greenberg JH, Karp JS, Kung HF, Shiue CY: N, N-dimethyl-2-(2-amino-4-[18 F]-fluorophenylthio)-benzylamine (4-[18 F]-ADAM): an improved PET radioligand for serotonin transporters. J Nucl Med 2003, 44:1890–1897.PubMed
31.
Wang JL, Parhi AK, Oya S, Lieberman B, Kung MP, Kung HF: 2-(2′-((Dimethylamino) methyl)-4′-(3-[ 18   F]fluoropropoxy)-phenylthio) benzenamine for positron emission tomography imaging of serotonin transporters. Nucl Med Biol 2008, 35:447–458.CrossRefPubMedPubMedCentral
32.
Ma KH, Huang WS, Kuo YY, Peng CJ, Liou NH, Liu RS, Hwang JJ, Liu JC, Chen HJ, Shiue CY: Validation of 4-[ 18   F]-ADAM as a SERT imaging agent using micro-PET and autoradiography. Neuroimage 2009, 45:687–693.CrossRefPubMed
33.
Chen YA, Huang WS, Lin YS, Cheng CY, Liu RS, Wang SJ, Li I, Huang SY, Shiue CY, Chen CY, Ma KH: Characterization of 4-[ 18   F]-ADAM as an imaging agent for SERT in non-human primate brain using PET: a dynamic study. Nucl Med Biol 2012, 39:279–285.CrossRefPubMed
34.
Huang Y, Bae SA, Zhu Z, Hwang DR, Narendran R, Talbot PS, Hackett E, Kegeles LS, Laruelle M: [ 18   F]AFM is a specific PET radiotracer for the serotonin transporters: comparison with [ 11 C]AFM. Neuroimage 2002, 16:S2.
35.
Huang YY, Ma KH, Tseng TW, Chou TK, Ng H, Mirsalis JC, Fu YK, Chu TC, Huang WS, Shiue CY: Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[ 18   F]-ADAM in rats and monkeys. Eur J Nucl Med Mol Imaging 2010, 37:545–555.CrossRefPubMed
36.
Huang W-S, Huang S-Y, Ho P-S, Ma K-H, Huang Y-Y, Yeh C-B, Liu R-S, Cheng C-Y, Shiue C-Y: PET imaging of the brain serotonin transporters (SERT) with N, N-dimethyl-2-(2-amino-4-[18 F]fluorophenylthio)benzylamine (4-[18 F]-ADAM) in humans: a preliminary study. Eur J Nucl Med Mol Imaging 2013, 40:115–124.CrossRefPubMed
37.
Food and Drug Administration: Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Division of Drug Information. Rockville: Center for Drug Evaluation and Research; 2005.
38.
Terry GE, Hirvonen J, Liow JS, Seneca N, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Pike VW: Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB 1 receptors using positron emission tomography. Eur J Nucl Med Mol Imaging 2010, 37:1499–1506.CrossRefPubMedPubMedCentral
39.
Kimura Y, Siméon FG, Hatazawa J, Mozley PD, Pike VW, Innis RB, Fujita M: Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18   F-SP203, to image metabotropic glutamate subtype 5 receptors in humans. Eur J Nucl Med Mol Imaging 2010, 37:1943–1949.CrossRefPubMedPubMedCentral
40.
Bélanger M-J, Simpson NR, Wang T, Van Heertum RL, Mann JJ, Parsey RV: Biodistribution and radiation dosimetry of [ 11 C]DASB in baboons. Nucl Med Biol 2004, 31:1097–1102.CrossRefPubMed
41.
ICRP: ICRP Publication 23: Report of the Task Group on Reference Man. Oxford: Pergamon; 1975.
42.
ICRP: ICRP Publication 89: Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. A report of Age- and Gender-Related Differences in the Anatomical and Physiological Characteristics of Reference Individuals. Oxford: Pergamon; 2002.
43.
Tipre DN, Lu JQ, Fujita M, Ichise M, Vines D, Innis RB: Radiation dosimetry estimates for the PET serotonin transporter probe 11 C-DASB determined from whole-body imaging in non-human primates. Nucl Med Commun 2004, 25:81–86.CrossRefPubMed
44.
Cupp CJ, Uemura E: Body and organ weights in relation to age and sex in Macaca mulatta. J Med Primatol 1981, 10:110–123.PubMed
45.
Stabin MG, Tagesson M, Thomas SR, Ljungberg M, Strand SE: Radiation dosimetry in nuclear medicine. Appl Radiat Isot 1999, 50:73–87.CrossRefPubMed
46.
Stabin MG, Sparks RB, Crowe E: OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46:1023–1027.PubMed
47.
ICRP: Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Oxford: Pergamon; 1991.
48.
Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001, 108:1141–1150.CrossRefPubMedPubMedCentral
49.
Schroeter S, Levey A, Blakely R: Polarized expression of the antidepressant-sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland. Mol Cell Neurosci 1997, 9:170–184.CrossRefPubMed
50.
Mortensen O, Kristensen A, Rudnick G, Wiborg O: Molecular cloning, expression and characterization of a bovine serotonin transporter. Brain Res Mol Brain Res 1999, 71:120–126.CrossRefPubMed
51.
Marjamäki P, Zessin J, Eskola O, Grönroos T, Haaparanta M, Bergman J, Lehikoinen P, Forsback S, Brust P, Steinbach J: S‐[18 F]fluoromethyl‐(+)‐McN5652, a PET tracer for the serotonin transporter: evaluation in rats. Synapse 2003, 47:45–53.CrossRefPubMed
52.
Schmidt BJ, Jordan LM: The role of serotonin in reflex modulation and locomotor rhythm production in the mammalian spinal cord. Brain Res Bull 2000, 53:689–710.CrossRefPubMed
53.
Sur C, Betz H, Schloss P: Localization of the serotonin transporter in rat spinal cord. Eur J Neurosci 1996, 8:2753–2757.CrossRefPubMed
54.
ICRP: Radiological protection and safety in medicine. ICRP Publication 73. Anne ICRP 1996, 26(2):1–47.CrossRef
55.
EU: Radiation protection 99. Guidance on Medical Exposures in Medical and Biomedical Research. Directorate-General on Environment, Nuclear Safety and Civil Protection. Luxembourg, Belgium; 1998.
56.
Fooden J: Comparative review of fascicularis-group species of Macaques (primates: Macaca). Fieldiana Zool 2006, 107:1–43.
57.
Mouri T, Agatsuma T, Iwagami M, Kawamoto Y: Species identification by mitochondrial DNA: a case study of macaque remains from Shuri castle, Okinawa (in Japanese with English summary). Primate Res 2000, 16:87–94.CrossRef
58.
Lu J-Q, Ichise M, Liow J-S, Ghose S, Vines D, Innis RB: Biodistribution and radiation dosimetry of the serotonin transporter ligand 11 C-DASB determined from human whole-body PET. J Nucl Med 2004, 45:1555–1559.PubMed
59.
Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M: The radiation dosimetry of 2 [ 18   F]fluoro-2-deoxy-D-glucose in man. J Nucl Med 1982, 23:613–617.PubMed
60.
Dhawan V, Belakhlef A, Robeson W, Ishikawa T, Margouleff C, Takikawa S, Chaly T, Kazumata K, Margouleff D, Eidelberg D: Bladder wall radiation dose in humans from fluorine-18-FDOPA. J Nucl Med 1996, 37:1850–1852.PubMed
Metadata
Title
Toxicity and radiation dosimetry studies of the serotonin transporter radioligand [18 F]AFM in rats and monkeys
Authors
Ya-Yao Huang
Chen-Yi Cheng
Wen-Sheng Huang
Kuo-Hsing Ma
Ta-Wei Tseng
Ta-Kai Chou
Yiyun Huang
Chyng-Yann Shiue
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2014
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-014-0071-1

Other articles of this Issue 1/2014

EJNMMI Research 1/2014 Go to the issue

Original research

A pilot study of 4′-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer

Original research

Correction of scan time dependence of standard uptake values in oncological PET

Original research

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

Preliminary research

Radiation dosimetry of florbetapir F 18

Original research

Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy

Original Research

Utility of 18 F-FDG and 11C-PBR28 microPET for the assessment of rat aortic aneurysm inflammation